Should high risk smoldering myeloma be treated outside a clinical trial: NO

Morie A. Gertz; Iuliana Vaxman

doi:10.1080/10428194.2021.1951723

Should high risk smoldering myeloma be treated outside a clinical trial: NO

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2565-2567
Number of pages	3
Journal	Leukemia and Lymphoma
Volume	62
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2021.1951723
State	Published - 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2021.1951723

Cite this

@article{c35d775635b4444593628c91b65331b8,

title = "Should high risk smoldering myeloma be treated outside a clinical trial: NO",

author = "Gertz, {Morie A.} and Iuliana Vaxman",

year = "2021",

doi = "10.1080/10428194.2021.1951723",

language = "English (US)",

volume = "62",

pages = "2565--2567",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Should high risk smoldering myeloma be treated outside a clinical trial

T2 - NO

AU - Gertz, Morie A.

AU - Vaxman, Iuliana

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85118558180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118558180&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1951723

DO - 10.1080/10428194.2021.1951723

M3 - Comment/debate

C2 - 34261405

AN - SCOPUS:85118558180

SN - 1042-8194

VL - 62

SP - 2565

EP - 2567

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

Should high risk smoldering myeloma be treated outside a clinical trial: NO

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this